We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Swiss group rethinks NHS collaboration after low take-up of treatment during rollout via GPs
Companies want incentives to create jobs and stave off competition from China
MHRA chief in talks with watchdogs in Australia, Canada, Singapore and Switzerland to create partnership
Life sciences and AI groups welcome UK government’s rethink on tax credits, but less cutting-edge start-ups face funding drop
With the latest credit for research intensive businesses, the government is picking winners by the back door
A Nasdaq-listed company is trialling the active ingredient in magic mushrooms as a new treatment
High hurdles and pricing reforms mean companies will need ingenuity to achieve a premium
Some of the world’s biggest health challenges do not lend themselves to conventional investment
Pharma chief says sector is seen as ‘niche’ and leaves women suffering from healthcare inequality
The FT examines the causes and effects of an increasing global resistance to antibiotics: from the pressures doctors are under to prescribe them, to what new treatments are currently in the pipeline, as well as what role can the consumer play in reducing antibiotic use in the food chain
Chief executive Paul Hudson sounds the alarm over British government’s cuts to research
The chancellor’s use of advanced software to help write a speech was neat and unfortunate
UK biotech racing to keep antibody up to date with latest variants
Move threatens Britain’s standing as a tech hub and government ambitions to grow the sector
The decline in truly revolutionary research may have serious implications for humanity
Business groups cautiously welcome acknowledgment that reform ‘creates challenges for some SMEs’
Government keeps EU research programmes in its sights but pushes ahead with other plans
Agreement is one of several announced as major healthcare conference begins in San Francisco
Daiichi Sankyo and AstraZeneca’s Enhertu could double time patients can live without their condition progressing
Success in battle against Covid does not ensure success against tumours, but should narrow the odds
Chief commercial officer Luke Miels looking at targets worth up to $2.5bn
Eli Lilly, Amgen, Pfizer and Regeneron follow Novo Nordisk into obesity treatments worth billions
From obesity drugs to cancer treatments, this year should be remembered for pharmaceutical advances
Former Johnson & Johnson executive ‘on the look out’ for rivals amid biotech sell-off
CSL’s $3.5mn single-dose treatment for haemophilia sparks debate over how to pay for revolutionary drugs
International Edition
